All In MedTech

Device Trial Radar · NCT05313984

OptiLUTS Part C: the Development of a Symptom Assessment Tool in Sacral Neuromodulation.

Optimization of Therapy Resistant LUTS (OptiLUTS) Part C: the Development of a Symptom Assessment Tool in Sacral Neuromodulation: a Prospective Single Centre Study.

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

93

Actual

Start

Mar 1, 2018

Primary completion

Dec 1, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
University Hospital, GhentAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medtronic
First posted
Apr 6, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Sacral neuromodulation (SNM) is a two-staged 2nd-line therapy for therapy-resistant LUTS and fecal incontinence. Currently, the assessment of symptoms at baseline and after stage I is directed towards a discipline related evaluation. The OptiLUTS trial strives for a more holistic approach, taking all pelvic floor dysfunctions into account. A holistic assessment tool will be developed and SNM-care pathway will be set-up.

Conditions

  • Overactive Bladder Syndrome
  • Urinary Retention
  • Dysfunctional Voiding
  • Fecal Incontinence
  • Fowler Syndrome

Interventions

  • Sacral neuromodulationDevice

    Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic). Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Implantation ratioTime frame: Through study completion, an average of 3 years
  2. True success ratioTime frame: Through study completion, an average of 3 years
  3. False positive ratioTime frame: One month after definitive implant.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Urology, Ghent University Hospital

    Ghent, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.